98%
921
2 minutes
20
A 76-year-old woman with advanced pancreatic cancer developed recurrent cholecystitis after covered self-expandable metal stent (CSEMS) placement. The cholecystitis was refractory to repeated percutaneous transhepatic gallbladder drainage (PTGBD). Cholecystography showed a patent cystic duct with right and cranial side bifurcation, which is indicative of an increased likelihood of success of endoscopic transpapillary gallbladder drainage (ETGBD). We were able to manage the cholecystitis by ETGBD without further recurrence. ETGBD is considered an effective internal drainage method for the management of acute cholecystitis after CSEMS placement, and its indication may be decided on the basis of the findings of cholecystography through the PTGBD route.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908391 | PMC |
http://dx.doi.org/10.2169/internalmedicine.9706-22 | DOI Listing |
Dig Endosc
September 2025
Department of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Ann Med Surg (Lond)
September 2025
Internal Medicine Department, Chirayu National Hospital and Medical Institute (CNHMI), Maharajgunj, Kathmandu, Nepal.
Introduction: Laparoscopic cholecystectomy (LC) is the gold standard for gallbladder pathologies, but carries risks of bile duct injury (BDI) and vascular complications, such as hepatic artery pseudoaneurysm (HAP). While BDI occurs in 0.3-0.
View Article and Find Full Text PDFJ Adv Res
August 2025
Department of Oncology and Laparoscopy Surgery, The First Affiliated Hospital of Harbin Medical University, 150000 Harbin, Heilongjiang Province, China; Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, 150000 Harbin, Heilongj
Introduction: Acute pancreatitis (AP) is one of the most common gastrointestinal diseases, imposing a significant burden on patients, with its incidence steadily increasing worldwide. Despite a drop in fatality rates, AP-related complications remain high, impacting prognosis.
Objectives: This retrospective clinical study introduces the concept of "bile transfer" (BT) and explores its potential in reducing AP-related complications.
Biomedicines
August 2025
Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 3718511, Gunma, Japan.
: The TOPAZ-1 phase III trial reported a survival benefit of using durvalumab, an anti-programmed death ligand 1 (anti-PD-L1) antibody, in combination with gemcitabine and cisplatin (GCD) treatment in patients with advanced biliary tract cancer. This retrospective study investigated the efficacy and safety of GCD treatment for advanced biliary tract cancer in real-world conditions. : The study subjects were 52 patients with biliary tract cancer who received GCD therapy between January 2023 and May 2024.
View Article and Find Full Text PDFEndosc Int Open
July 2025
Gastroenterology Division, University of California San Francisco Medical Center, San Francisco, United States.